Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Humana Press Country of Publication: United States NLM ID: 9434444 Publication Model: Print Cited Medium: Print ISSN: 1355-008X (Print) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE
    • Publication Information:
      Publication: Feb. 1996- : Totowa, NJ : Humana Press
      Original Publication: Houndsmills, Basingstoke, Hants, UK : Macmillan Press, c1994-
    • Subject Terms:
      Carbamates/*pharmacology ; Glucose Solution, Hypertonic/*pharmacology ; Hypoglycemic Agents/*pharmacology ; Insulin/*metabolism ; Islets of Langerhans/*metabolism ; Piperidines/*pharmacology; Animals ; Benzamides/pharmacology ; Blood Glucose/metabolism ; Female ; Insulin/blood ; Insulin Secretion ; Islets of Langerhans/drug effects ; Rats ; Rats, Wistar ; Stereoisomerism
    • Abstract:
      This study investigates the insulin secretory responsiveness of pancreatic islets to repaglinide in an experimental model of B-cell glucose incompetence. Rats were infused for 2 d with a 1.67 M solution of D-glucose administered at a rate close to 2.8 mL/h. This resulted in a modest rise in glycemia, a severe increase in plasma insulin concentration, an increased sensitivity of B-cells to adrenergic stress, an abnormally high insulin output from isolated islets perifused in the presence of 16.7 mM D-glucose, and a paradoxical transient increase in insulin release from the islets in response to a fall in hexose concentration. The early increment in insulin output evoked by repaglinide, in the presence of 16.7 mM D-glucose, was not lower in the islets from glucose-infused rats than in those from control rats. Moreover, when the meglitinide analog was administered concomitantly with the removal of D-glucose from the perifusion medium, the early response to repaglinide was further increased. Even after 24 min of glucose deprivation, the output of insulin by the islets from glucose-infused rats was higher in the presence of repaglinide than in its absence. These findings indicate that, in this model of B-cell dysfunction, the secretory responsiveness to repaglinide, as distinct from that to glucose, is fully preserved. Therefore, when taken into consideration together with prior observations, these findings argue in support of the use of this insulinotropic agent in the treatment of noninsulin-dependent diabetes.
    • References:
      Pharmacol Res. 1996 Sep-Oct;34(3-4):105-8. (PMID: 9051699)
      Res Commun Mol Pathol Pharmacol. 1997 Jul;97(1):53-9. (PMID: 9507568)
      Metabolism. 1990 Jan;39(1):87-95. (PMID: 2403623)
      Diabetes Res. 1993;23(2):55-63. (PMID: 7712680)
      Diabetes Res. 1994;27(2):81-7. (PMID: 7671557)
      Metabolism. 1992 Aug;41(8):814-9. (PMID: 1640857)
      Pharmacol Res. 1996 Jul-Aug;34(1-2):83-5. (PMID: 8981561)
      J Clin Invest. 1993 Feb;91(2):432-6. (PMID: 8432852)
      Biochem Med Metab Biol. 1994 Apr;51(2):129-39. (PMID: 7519027)
      Diabetes Res Clin Pract. 1989 Apr 1;6(3):191-8. (PMID: 2656169)
      Eur J Pharmacol. 1997 Sep 24;335(2-3):227-34. (PMID: 9369378)
      J Physiol. 1978 Oct;283:409-24. (PMID: 364009)
      Endocrinology. 1985 Mar;116(3):1168-74. (PMID: 2857640)
      Pharmacol Res. 1997 Nov;36(5):369-72. (PMID: 9441727)
    • Accession Number:
      0 (Benzamides)
      0 (Blood Glucose)
      0 (Carbamates)
      0 (Glucose Solution, Hypertonic)
      0 (Hypoglycemic Agents)
      0 (Insulin)
      0 (Piperidines)
      668Z8C33LU (repaglinide)
      8V6OK1I088 (meglitinide)
    • Publication Date:
      Date Created: 19980919 Date Completed: 19981124 Latest Revision: 20220716
    • Publication Date:
      20221213
    • Accession Number:
      10.1385/ENDO:8:3:247
    • Accession Number:
      9741829